-
公开(公告)号：US20090062213A1
公开(公告)日：2009-03-05
申请号：US12167852
申请日：2008-07-03
CPC分类号： G01N33/6896 , A61K38/06 , C12Q1/26 , G01N33/88 , G01N2500/00
摘要： The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided.
摘要翻译： 本发明涉及用于调节与同源配体的PDZ结构域相互作用的组合物。 还提供了评估和表征各种多肽的PDZ结构域相互作用的方法。
-
公开(公告)号：US08633160B2
公开(公告)日：2014-01-21
申请号：US12167852
申请日：2008-07-03
CPC分类号： G01N33/6896 , A61K38/06 , C12Q1/26 , G01N33/88 , G01N2500/00
摘要： The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided.
摘要翻译： 本发明涉及用于调节与同源配体的PDZ结构域相互作用的组合物。 还提供了评估和表征各种多肽的PDZ结构域相互作用的方法。
-
3.发明授权公开(公告)号：US09061070B2
公开(公告)日：2015-06-23
申请号：US13620438
申请日：2012-09-14
申请人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
发明人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
CPC分类号： A61K47/48246 , A61K38/00 , A61K47/645 , C07K7/06 , C07K14/70571 , C07K2319/10
摘要： The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.
摘要翻译： 本发明提供了治疗中风和组合物的方法。 该方法采用活性肽和内化肽的嵌合肽。 内化肽是一种tat变体，其促进其自身的摄取和连接的活性肽进入细胞，而不与N型钙通道基本结合。 使用tat变体允许治疗与结合N-型钙通道相关的某些副作用。 Tat变体肽也可以连接到其他活性剂以用于治疗其它疾病。
-
公开(公告)号：US08536129B2
公开(公告)日：2013-09-17
申请号：US13186418
申请日：2011-07-19
申请人： Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
发明人： Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
IPC分类号： A61K38/04
CPC分类号： A61K38/1787 , A61K38/07
摘要： The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.
摘要翻译： 本发明提供了治疗或预防患有或有发生焦虑症状的患者的方法，其中向患者施用抑制PSD95与NMDA受体的特异性结合的药剂的有效方案。
-
5.发明申请公开(公告)号：US20080274977A1
公开(公告)日：2008-11-06
申请号：US12040851
申请日：2008-02-29
申请人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
发明人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
CPC分类号： A61K47/48246 , A61K38/00 , A61K47/645 , C07K7/06 , C07K14/70571 , C07K2319/10
摘要： The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.
摘要翻译： 本发明提供了治疗中风和组合物的方法。 该方法采用活性肽和内化肽的嵌合肽。 内化肽是一种tat变体，其促进其自身的摄取和连接的活性肽进入细胞，而不与N型钙通道基本结合。 使用tat变体允许治疗与结合N-型钙通道相关的某些副作用。 Tat变体肽也可以连接到其他活性剂以用于治疗其它疾病。
-
公开(公告)号：US20120083449A1
公开(公告)日：2012-04-05
申请号：US13186418
申请日：2011-07-19
申请人： Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
发明人： Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
CPC分类号： A61K38/1787 , A61K38/07
摘要： The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.
摘要翻译： 本发明提供了治疗或预防患有或有发生焦虑症状的患者的方法，其中向患者施用抑制PSD95与NMDA受体的特异性结合的药剂的有效方案。
-
公开(公告)号：US08324168B2
公开(公告)日：2012-12-04
申请号：US12553096
申请日：2009-09-03
申请人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
发明人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
IPC分类号： C07K14/435 , A61K38/16
摘要： The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.
摘要翻译： 本发明提供可用于治疗疼痛的药剂。 一个示例性药剂包含一部分逆转录病毒Tat蛋白或由其组成。 一种这样的药剂是Tat-NR2B9c肽。 此肽以前已经被描述为通过抑制与NMDA受体和/或NOS的PSD95相互作用来抑制中风和类似条件的损伤作用的药剂。 本申请提供了显示Tat-NR2B9c肽有效缓解疼痛的数据。 疼痛缓解可以在低于抑制PSD-95与NMDAR或NOS相互作用所需剂量的肽剂量下获得。
-
8.发明授权公开(公告)号：US08288345B2
公开(公告)日：2012-10-16
申请号：US12040851
申请日：2008-02-29
申请人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
发明人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
CPC分类号： A61K47/48246 , A61K38/00 , A61K47/645 , C07K7/06 , C07K14/70571 , C07K2319/10
摘要： The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.
摘要翻译： 本发明提供了治疗中风和组合物的方法。 该方法采用活性肽和内化肽的嵌合肽。 内化肽是一种tat变体，其促进其自身的摄取和连接的活性肽进入细胞，而不与N型钙通道基本结合。 使用tat变体允许治疗与结合N-型钙通道相关的某些副作用。 Tat变体肽也可以连接到其他活性剂以用于治疗其它疾病。
-
公开(公告)号：US20100062985A1
公开(公告)日：2010-03-11
申请号：US12553096
申请日：2009-09-03
申请人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
发明人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
摘要： The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.
摘要翻译： 本发明提供可用于治疗疼痛的药剂。 一个示例性药剂包含一部分逆转录病毒Tat蛋白或由其组成。 一种这样的药剂是Tat-NR2B9c肽。 此肽以前已经被描述为通过抑制与NMDA受体和/或NOS的PSD95相互作用来抑制中风和类似条件的损伤作用的药剂。 本申请提供了显示Tat-NR2B9c肽有效缓解疼痛的数据。 疼痛缓解可以在低于抑制PSD-95与NMDAR或NOS相互作用所需剂量的肽剂量下获得。
-
公开(公告)号：US20090036376A1
公开(公告)日：2009-02-05
申请号：US12165983
申请日：2008-07-01
申请人： Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
发明人： Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
CPC分类号： A61K38/1787 , A61K38/07
摘要： The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.
摘要翻译： 本发明提供了治疗或预防患有或有发生焦虑症状的患者的方法，其中向患者施用抑制PSD95与NMDA受体的特异性结合的药剂的有效方案。
-
-
-
-
-
-
-
-
-
搜索结果
49 条记录 (耗时 0.037 秒)
